We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

173 hedge funds and large institutions have $209M invested in Revance Therapeutics, Inc. in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 42 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more call options, than puts

Call options by funds: $1.57M | Put options by funds: $775K

50% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less funds holding

Funds holding: 188 → 173 (-15)

34% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 41

49% less capital invested

Capital invested by funds: $411M → $209M (-$202M)

Holders
173
Holders Change
-15
Holders Change %
-7.98%
% of All Funds
2.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
63
Reduced
42
Closed
41
Calls
$1.57M
Puts
$775K
Net Calls
+$797K
Net Calls Change
-$1.25M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.28M
2
SCM
Stonepine Capital Management
Oregon
+$2.81M
3
N
Nuveen
North Carolina
+$2.4M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$2.3M
5
Millennium Management
Millennium Management
New York
+$2.06M

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$10.2M
2
CIBC Asset Management
CIBC Asset Management
Ontario, Canada
-$8.56M
3
SCM
Suvretta Capital Management
New York
-$5.26M
4
OM
Opaleye Management
Massachusetts
-$3.86M
5
Marshall Wace
Marshall Wace
United Kingdom
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
201
Accredited Investors
Minnesota
– -$63.2K -12,845 Closed
CCP
202
Clarity Capital Partners
California
– -$59.4K -12,082 Closed
Creative Planning
203
Creative Planning
Kansas
– -$56.8K -11,551 Closed
MLICM
204
Metropolitan Life Insurance Company (MetLife)
New York
– -$17.9K -3,633 Closed
RTC
205
Riverview Trust Company
Washington
– -$15.9K -3,237 Closed
FFWM
206
Future Financial Wealth Management
Ohio
– -$9.84K -2,000 Closed
GI
207
GAMMA Investing
California
– -$5.07K -1,030 Closed
QCG
208
Quadrant Capital Group
Ohio
– -$1.97K -400 Closed
PNC Financial Services Group
209
PNC Financial Services Group
Pennsylvania
– -$1.03K -210 Closed
CFD
210
Creative Financial Designs
Indiana
– -$984 -200 Closed
AssetMark Inc
211
AssetMark Inc
California
– -$335 -68 Closed
EC
212
Elequin Capital
New York
– -$162 -33 Closed
AWM
213
Avior Wealth Management
Nebraska
– -$83 -17 Closed
C
214
Covestor
United Kingdom
– +$55 +16 +160%
5 6 7 8
9

RVNC Hedge Fund Activity: Q2 2024 in Review

173 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2024, worth a combined $209M — down 49% from $411M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of RVNC and 27 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 63 added.

The largest buyer was BlackRock, adding an estimated $4.28M. The largest seller was Barclays, cutting an estimated $10.2M.

  • 173 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2024, down from 188 in Q1 2024.
  • Funds reported $209M of Revance Therapeutics, Inc. stock for Q2 2024, down 49% quarter-over-quarter.
  • 27 funds opened new Revance Therapeutics, Inc. positions in Q2 2024 and 41 closed out, a net change of -14 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q2 2024 was BlackRock, an estimated $4.28M added.
  • The largest Revance Therapeutics, Inc. seller in Q2 2024 was Barclays, an estimated $10.2M sold.

Based on aggregated 13F filings for Q2 2024.